Brief: Hua Medicine Says Unit Enters Collaboration Agreement With Bayer Healthcare
17/08/2020 11:33
Aug 17 (Reuters) - Hua Medicine 2552.HK :
* UNIT ENTERED INTO A COLLABORATION AGREEMENT WITH BAYER
HEALTHCARE
* AGREEMENT TO COMMERCIALIZE AND FORM A STRATEGIC
PARTNERSHIP FOR
DORZAGLIATIN, A NOVEL DIABETES TREATMENT, IN CHINA
* CO WILL RECEIVE UPFRONT PAYMENT OF RMB300 MILLION AND
ADDITIONAL
PAYMENTS COULD REACH UP TO RMB4.18 BILLION IF CERTAIN MILESTONES
ARE MET
Source text for Eikon: ID:nHKS85ltv4
Further company coverage: 2552.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hua Medicine
See all newsBrief: Hua Medicine Expects Loss Of RMB30.2 Mln For HY
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY